INCANNEX HEALTHCARE INC.

Communiqués Incannex Healthcare Inc.

Actions

IXHL

US45333F1093

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 31/05/2024			Varia. 5j.	Varia. 1 janv.
2,83 ^USD	-5,35%		+4,81%	-39,01%

30/05	Incannex Healthcare Inc. annonce le début du dosage des patients dans le cadre du protocole de l'essai clinique de phase 2/3 RePOSA visant à évaluer le médicament IHL-42X chez les patients souffrant d'apnée obstructive du sommeil	CI
15/05	Incannex Healthcare Inc. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	30/05	AQ
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	07/05	AQ
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	01/05	NE
Incannex Healthcare Inc. Quarterly Update, Q1 2024	16/04	AQ
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	28/02	AQ
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	16/02	AQ
Clarion Clinics Open for Psychedelic-Assisted Treatments	01/02	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	24/01	AQ
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	18/01	AQ
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	17/01	AQ
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia	21/12	AQ
Incannex Healthcare : Change in Certifying Accountants - Form 8-K	15/12	PU
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	06/12	AQ
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors	17/08/22	GL
Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion	10/05/22	PR
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M	28/04/22	PR
Incannex to Acquire APIRx Pharmaceuticals USA, LLC	24/03/22	PR
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies	10/03/22	PR
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics	03/03/22	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.

PROFITEZ-EN MAINTENANT